During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...

Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their ...

Sarcopenia, a hallmark of cancer cachexia, is associated with poor outcomes in chimeric antigen receptor (CAR) T-cell therapy ...

The co-founder and bassist for the group has released his first memoir, Fahrenheit-182, which details his formative years, ...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

Nkure Therapeutics and Crispr Therapeutics partner to develop off-the-shelf CAR T therapy for oncology in India.